The American Journal of Medicine
Volume 122, Issue 7 , Pages 688-691, July 2009

Herpes Simplex Type-2 Meningitis: Presentation and Lack of Standardized Therapy

  • Marie L. Landry, MD

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Conn
    • Corresponding Author InformationRequests for reprints should be addressed to Marie L. Landry, MD, Department of Laboratory Medicine, P.O. Box 208035, Yale University School of Medicine, New Haven, CT 06520-8035
  • ,
  • Jennifer Greenwold, MD

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Conn
    • Current address: 1493 Cambridge Street, Cambridge, MA 02139.
  • ,
  • Holenarasipur R. Vikram, MD

      Affiliations

    • Division of Infectious Diseases, Mayo Clinic, Scottsdale, Ariz

Abstract 

Background

Herpes simplex type-2 (HSV-2) causes both primary and recurrent lymphocytic meningitis, but optimal patient management is not well defined.

Methods

In this retrospective observational study, we reviewed the medical records of patients with HSV-2-positive cerebrospinal fluid samples in our laboratory between January 2001 and January 2005.

Results

During the study period, 23 patients, aged 16 to 83 years, had HSV-2 detected in spinal fluid. Nineteen (83%) had meningitis and 4 (17%) had evidence of meningoencephalitis. Seventy-four percent were female. Two (8.7%) had a history of prior genital herpes, and one (4.3%) had genital lesions noted at the time of presentation. Genital examinations were performed at presentation in only 3 patients. Seven (30.4%) patients reported previous episodes of meningitis. Two celibate women developed HSV-2 meningitis or meningoencephalitis following lumbar steroid injection for spinal stenosis. One woman developed HSV-2 meningoencephalitis 3 days postpartum following cesarean section. Antiviral treatment for uncomplicated HSV-2 meningitis varied from none (4 patients) to 14-21 days of intravenous (IV) acyclovir therapy (4 patients). The 11 remaining patients with meningitis received 1-7 days of IV therapy, followed by 7-21 days of oral antiviral therapy. Three of 4 patients with meningoencephalitis received 21 days of IV acyclovir, and one received 3 days IV acyclovir followed by 14 days of oral therapy.

Conclusions

HSV-2 meningitis presents most often without a history of genital herpes, recurrent meningitis, or genital symptoms. Current management practices are highly variable and may lead to unnecessary hospitalization and prolonged intravenous therapy.

Keywords: Antiviral therapy, Genital herpes, Herpes simplex type-2, HSV-2 encephalitis, HSV-2 meningitis, Recurrent meningitis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: None.

 Conflict of Interest: None.

 Authorship: All authors had access to the data and a role in writing the manuscript.

PII: S0002-9343(09)00289-7

doi:10.1016/j.amjmed.2009.02.017

The American Journal of Medicine
Volume 122, Issue 7 , Pages 688-691, July 2009